drugset / Trial / NCT01670019

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

NCT01670019

Phase 4 Completed 46 enrolled Duke University Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing antidepressant treatment in patients with major depression who have not had a complete therapeutic response to treatment with the antidepressant alone. The investigators hypothesize that added asenapine will produce greater reductions in depression than will added placebo.

Timeline

Start
2012-10
Primary completion
2014-05
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Asenapine Other / unclassified 5 mg
Subject Asenapine Other / unclassified 10 mg
Subject Asenapine Other / unclassified 15 mg
Subject Asenapine Other / unclassified 20 mg